Pantoprazole for Acute Kidney Injury Prevention Post-Cardiac Surgery
Trial Summary
Do I need to stop taking my current medications for this trial?
The protocol does not specify if you need to stop taking your current medications. However, if you are taking proton pump inhibitors (PPIs) and have a hypersensitivity to them, you may be excluded from the trial.
What data supports the idea that Pantoprazole for Acute Kidney Injury Prevention Post-Cardiac Surgery is an effective drug?
The available research does not provide any data on Pantoprazole for preventing acute kidney injury after cardiac surgery. Instead, the studies focus on different treatments related to organ transplantation, such as immunosuppressive drugs used to prevent organ rejection. Therefore, there is no information here to support the effectiveness of Pantoprazole for this specific use.12345
What safety data exists for pantoprazole in preventing acute kidney injury after cardiac surgery?
The provided research does not directly address the safety of pantoprazole for preventing acute kidney injury post-cardiac surgery. However, pantoprazole is a proton pump inhibitor with established use in treating acid-related diseases and has been compared to other treatments like ranitidine and omeprazole in various studies. These studies focus on its efficacy and safety in treating gastrointestinal conditions, but specific safety data for its use in preventing acute kidney injury post-cardiac surgery is not available in the provided research.678910
Is the drug Pantoprazole promising for preventing kidney injury after heart surgery?
What is the purpose of this trial?
The purpose of this study is to determine whether perioperative intravenous administration of pantoprazole will improve kidney function parameters following cardiac surgery with cardiopulmonary bypass compared to famotidine and to determine whether perioperative intravenous administration of pantoprazole will decrease the incidence of postoperative Acte Kidney Injury (AKI) and major adverse kidney events (MAKE).
Research Team
Yafen Liang, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Eligibility Criteria
This trial is for adults scheduled for elective cardiac surgery with a high risk of acute kidney injury (AKI), as indicated by a Cleveland risk score over 6. They must have normal preoperative kidney function and not be on dialysis, pregnant, nursing, allergic to PPIs, or have liver disease or vitamin B12 deficiency.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either pantoprazole or famotidine perioperatively for 2 days
Immediate Postoperative Monitoring
Monitoring of kidney injury biomarkers (KIM-1 and NGAL) at 8, 24, and 48 hours postoperatively
Follow-up
Participants are monitored for major adverse kidney events and AKI incidence up to 30 days post-surgery
Treatment Details
Interventions
- Famotidine
- Pantoprazole
Famotidine is already approved in United States, European Union, Canada, Japan for the following indications:
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Peptic ulcer disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center, Houston
Lead Sponsor
Society of Cardiovascular Anesthesiologists
Collaborator